SCHEMBL2486918

SCHEMBL2486918

COCCN1CCN(CCc2ccc(Nc3ncc4c(n3)-c3ccccc3C(c3cccc(Br)c3)C4)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.51
FGFR2 P21802 2/20 0.51
CSF1R P07333 1/20 0.51
FGFR3 P22607 1/20 0.51
ACVR1 Q04771 1/20 0.44
KDR P35968 9/20 0.43
CDK1 P06493 8/20 0.43
AURKA O14965 1/20 0.39
CDK4 P11802 1/20 0.39
MEN1 O00255 2/20 0.38
USP2 O75604 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CASP1 P29466 2/20 0.38
CYP2C19 P33261 2/20 0.38
CASP7 P55210 2/20 0.38
KMT2A Q03164 2/20 0.38
HIF1A Q16665 2/20 0.38
AXL P30530 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806869 1.00 FGFR1 (0.51) FGFR1FGFR2CSF1RFGFR3ACVR1
Hydrochloric Acid SCHEMBL2489901 0.99 FGFR1 (0.50) FGFR1FGFR2CSF1RFGFR3ACVR1
Hydrochloric Acid SCHEMBL2804799 0.99 FGFR1 (0.50) FGFR1FGFR2CSF1RFGFR3ACVR1
SCHEMBL2492521 0.93 KDR (0.49) FGFR1FGFR2CSF1RFGFR3KDR
SCHEMBL14644897 0.92 FGFR1 (0.50) FGFR1FGFR2CSF1RFGFR3ACVR1
SCHEMBL14644900 0.92 FGFR1 (0.50) FGFR1FGFR2CSF1RFGFR3ACVR1
SCHEMBL2806454 0.92 FGFR1 (0.50) FGFR1FGFR2CSF1RFGFR3ACVR1
SCHEMBL2490718 0.92 FGFR1 (0.53) FGFR1FGFR2CSF1RFGFR3ACVR1
Hydrochloric Acid SCHEMBL2804003 0.92 FGFR1 (0.49) FGFR1FGFR2CSF1RFGFR3ACVR1
Hydrochloric Acid SCHEMBL2490714 0.92 FGFR1 (0.49) FGFR1FGFR2CSF1RFGFR3ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379506-B1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS ARQULE INC (US) 2015-09-02 EP disclosed
EP-2379506-B1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS ARQULE INC (US) 2015-09-02 EP disclosed
US-8357694-B2 Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds ARQULE, INC. (US) 2013-01-22 US disclosed
US-8357694-B2 Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds ARQULE, INC. (US) 2013-01-22 US disclosed
US-8357694-B2 Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds ARQULE, INC. (US) 2013-01-22 US disclosed
EP-2379506-A1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS ArQule, Inc. (US) 2011-10-26 EP disclosed
US-20100239525-A1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239525-A1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078421-A1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F] ISOQUINOLIN-2-AMINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed
WO-2010078421-A1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F] ISOQUINOLIN-2-AMINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239525-A1 SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS NQO1, DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 FGFR1 530/4885FGFR2 511/4885CSF1R 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.